Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations
Third Quarter 2024 Results Key Financial Results Revenue: US$1.14m (down 55%
Bolt Biotherapeutics Reports Q3 2024 Financial Results
Bolt Biotherapeutics, Inc. ( (BOLT) ) has released its Q3 earnings. Here is a breakdown of the information Bolt Biotherapeutics, Inc. presented
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share. The company posted revenue of $1.1 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $1 million.
Inspire Veterinary Partners Reports Third Quarter 2024 Financial Results
Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (”Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported its financial results for the third quarter and nine months
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastasesTop-line pivotal data
Freshpet, Inc. Reports Third Quarter 2024 Financial Results
Detailed price information for Freshpet Inc CS (FRPT-Q) from The Globe and Mail including charting and trades.
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
Bolt Biotherapeutics, Inc. (BOLT) has disclosed a new risk, in the Corporate Activity and Growth category. The restructuring initiative ...
Yahoo Finance2d
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.43 per share a year ago.
Nasdaq8d
Bolt Biotherapeutics presents updated preclinical data for BDC-4182
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 ...
Morningstar1mon
Bolt Biotherapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CNN1y
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody ...
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...
Business Insider1d
Stifel Nicolaus Remains a Hold on Bolt Biotherapeutics (BOLT)
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report), with a price target of $1.50. The company’s shares closed ...